Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

被引:60
作者
Gherardi, MM
Nájera, JL
Pérez-Jiménez, E
Guerra, S
García-Sastre, A
Esteban, M
机构
[1] CSIC, Dept Mol & Cellular Biol, Ctr Nacl Biotecnol, Madrid 28049, Spain
[2] CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA
关键词
D O I
10.1128/JVI.77.12.7048-7057.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Vaccines that elicit systemic and mucosal immune responses should be the choice to control human immunodeficiency virus (HIV) infections. We have previously shown that prime-boost immunizations with influenza virus Env and vaccinia virus (VV) WR Env recombinants induced an enhanced systemic CD8(+) T-cell response against HIV-1 Env antigen. In this report, we analyzed in BALB/c mice after priming with influenza virus Env the ability of two W recombinants expressing HIV-1 Env B (W WR Env and the highly attenuated modified W Ankara [MVA] Env) to boost cellular immune responses in the spleen and in the lymph nodes draining the genital and rectal tracts. Groups of mice were primed by the intranasal route with 10(4) PFU of influenza virus Env and boosted 14 days later by the intraperitoneal or intranasal route with 10(7) PFU of MVA Env or W WR Env, while the control group received two immunizations with influenza virus Env. We found that the combined immunization (Flu/VV) increased more than 60 times the number of gamma interferon-specific CD8(+) T cells compared to the Flu/Flu scheme. Significantly, boosting with MVA Env by the intraperitoneal route induced a response 1.25 or 2.5 times (spleen or genital lymph nodes) higher with respect to that found after the boost with W WR Env. Mice with an enhanced CD8(+) T-cell response also had an increased Th1/Th2 ratio, evaluated by the cytokine pattern secreted following in vitro restimulation with gp160 protein and by the specific immunoglobulin G2a (IgG2a)/IgG1 ratio in serum. By the intranasal route recombinant WR Env booster gave a more efficient immune response (10 and 1.3 times in. spleen and genital lymph nodes, respectively) than recombinant MVA Env. However, the scheme influenza virus Env/MVA Env increased four times the response in the spleen, giving a low but significant response in the genital lymph nodes compared with a single intranasal immunization with MVA Env. These results demonstrate that the combination Flu/MVA in prime-booster immunization regimens is an effective vaccination approach to generate cellular immune responses to HIV antigens at sites critical for protective responses.
引用
收藏
页码:7048 / 7057
页数:10
相关论文
共 45 条
[1]   Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines [J].
Amara, RR ;
Villinger, F ;
Staprans, SI ;
Altman, JD ;
Montefiori, DC ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (15) :7625-7631
[2]   Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity [J].
Belyakov, IM ;
Moss, B ;
Strober, W ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4512-4517
[3]   Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein [J].
Belyakov, IM ;
Wyatt, LS ;
Ahlers, JD ;
Earl, P ;
Pendleton, CD ;
Kelsall, BL ;
Strober, W ;
Moss, B ;
Berzofsky, JA .
JOURNAL OF VIROLOGY, 1998, 72 (10) :8264-8272
[4]   Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza [J].
Bender, BS ;
Rowe, CA ;
Taylor, SF ;
Wyatt, LS ;
Moss, B ;
Small, PA .
JOURNAL OF VIROLOGY, 1996, 70 (09) :6418-6424
[5]   Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina [J].
Bergquist, C ;
Johansson, EL ;
Lagergard, T ;
Holmgren, J ;
Rudin, A .
INFECTION AND IMMUNITY, 1997, 65 (07) :2676-2684
[6]   Recombinant viruses as a tool for therapeutic vaccination against human cancers [J].
Bonnet, MC ;
Tartaglia, J ;
Verdier, F ;
Kourilsky, P ;
Lindberg, A ;
Klein, M ;
Moingeon, P .
IMMUNOLOGY LETTERS, 2000, 74 (01) :11-25
[7]   The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys [J].
Durbin, AP ;
Wyatt, LS ;
Siew, J ;
Moss, B ;
Murphy, BR .
VACCINE, 1998, 16 (13) :1324-1330
[8]   Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract [J].
Ferko, B ;
Katinger, D ;
Grassauer, A ;
Egorov, A ;
Romanova, J ;
Niebler, B ;
Katinger, H ;
Muster, T .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (05) :1359-1368
[9]   Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice [J].
Ferko, B ;
Stasakova, J ;
Sereinig, S ;
Romanova, J ;
Katinger, D ;
Niebler, B ;
Katinger, H ;
Egorov, A .
JOURNAL OF VIROLOGY, 2001, 75 (19) :8899-8908
[10]   Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus [J].
Finerty, S ;
Stokes, CR ;
Gruffydd-Jones, TJ ;
Hillman, TJ ;
Barr, FJ ;
Harbour, DA .
VACCINE, 2001, 20 (1-2) :49-58